Miracell unveils stem cell centrifuge ‘SMART M-Cell2’ at BIO KOREA 2022… “We will increase accessibility to stem cell treatment!”
Miracell Co., Ltd. (CEO Shin Hyun-soon) participated in ‘BIO KOREA 2022’ held at COEX in Seoul from Wednesday, May 11th to Friday, May 13th.
Founded in 1986, Miracell manufactures medical devices, food products, cosmetics, and actively engages in wholesale, retail, trade, and import/export operations.
Furthermore, Miracell has accumulated expertise and know-how through continuous research and development in stem cells, and is introducing various technologies and products to further specialize in stem cell therapy.
Recognized for its outstanding stem cell research, Miracell won the Medical Korea Grand Prize in 2012. The following year, in 2013, it registered autologous stem cell therapy for critical limb ischemia (Buerger’s disease, diabetic foot, etc.) as a new medical technology. Since then, it has listed a variety of stem cell treatments for acute myocardial infarction, osteoarthritis, and osteoarthritis, as well as stem cell cosmetics and medical devices.
At this exhibition, Miracell introduced the “SMART M-Cell 2,” a bone marrow and blood stem cell collection medical device.
Designated as an innovative medical device and certified as a New Excellent Technology (NET), this stem cell extraction device extracts blood or bone marrow and centrifuges it to selectively isolate cells. The cells collected through this process can be used for personalized treatments for target patients.
Miracell’s Smart M-Cell 2 boasts the advantage of handling larger volumes of bone marrow or blood than commonly used autologous platelet-rich plasma (PRP) therapy devices. Officials explained that this naturally increases the amount of effective cells obtained from a single centrifugation process.
A Miracell representative stated, “Currently, Smart Mcell 2 has received European CE certification and is in the process of obtaining US FDA approval.”
“With technology that meets international standards, we expect to be able to target the global market. We also believe this will significantly transform the domestic market, which has been heavily reliant on imported products.”
They continued, “The public often perceives stem cell therapy as a treatment for the wealthy due to its high cost. Therefore, we aim to create an environment and atmosphere where anyone can receive stem cell therapy at a reasonable cost through our products. We will also continue to conduct research and development to further expand the scope of stem cell therapy.”
Meanwhile, ‘BIO KOREA 2022,’ now in its 17th year, was hosted by the Korea Health Industry Development Institute and North Chungcheong Province. BIO KOREA, with the participation of world-renowned scholars and business experts every year, has solidified its position as Korea’s leading international biohealth convention.
BIO KOREA 2022, which brings together domestic and international companies in the bio, pharmaceutical, medical device, cosmetics, and food industries, as well as interested companies and organizations from consulting, academia, and related organizations, featured diverse programs including conferences, business forums, exhibitions, and investment fairs.